Survodutide [2805997-46-8]

AdipoGen Life Sciences

Survodutide [2805997-46-8]

10

2805997-46-8

Research Use Only

>98%

C192H289N47O61

4231.7

Chemical. CAS: 2805997-46-8. Formula: C192H289N47O61. MW: 4231.7. Soluble in water (10mg/ml). Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4. - Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.

C[C@@H](C(N)=O)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CCCCNC(CNC(CNC([C@H](CO)NC(CNC([C@H](CO)NC(CNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC4=CC=C(O)C=C4)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC5=CC=C(O)C=C5)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC6=CC=CC=C6)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(N)=O)NC(C7(NC([C@H](CC8=CNC=N8)N)=O)CCC7)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

-20°C,2°C to 8°C

12352200